COBO VIII Åbyen Komplementar ApS: Financial statements 2017
CVR: 37432539
Source: annual report 2017, Danish Business Authority
01/01/2017 – 31/12/2017
COBO VIII Åbyen Komplementar ApS (CVR 37432539) has filed annual accounts for 2017. In 2017, the company reported a net result of DKK -8,000 compared with DKK 0 the year before. Equity in the 2017 report amounted to DKK 42,000. The solvency ratio was 87.5%.
- Profit/Loss
- DKK -8,000
- Equity
- DKK 42,000
- Total Assets
- DKK 48,000
Official annual report
Keep an eye on COBO VIII Åbyen Komplementar ApS
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2017
As of July 10, 2017, Morten Lykke has left the board of directors of COBO VIII Åbyen Komplementar ApS.
As of July 10, 2017, Rasmus Nørgaard has left the board of directors of COBO VIII Åbyen Komplementar ApS.
As of July 10, 2017, Rune Højby Kock has left the board of directors of COBO VIII Åbyen Komplementar ApS.
As of July 10, 2017, John Bødker is registered as director of COBO VIII Åbyen Komplementar ApS.
As of July 10, 2017, Niels Lorentz Nielsen is registered as director of COBO VIII Åbyen Komplementar ApS.
As of July 10, 2017, Morten Lykke has stepped down as director of COBO VIII Åbyen Komplementar ApS.
As of July 10, 2017, Andreas Odgaard Stampe Bagunck has stepped down as chairman of COBO VIII Åbyen Komplementar ApS.
On July 10, 2017, the company changed its name from Komplementarselskabet Resireal NSF-Innovater A3 ApS to COBO VIII Åbyen Komplementar ApS.
COBO VIII Åbyen Komplementar ApS has published its interim report for the period February 8, 2016 – December 31, 2016.
About COBO VIII Åbyen Komplementar ApS
COBO VIII Åbyen Komplementar ApS was a Danish company of the type Anpartsselskab based in København V, founded in 2016. The company has been dissolved on 10 June 2024. The company was registered under the industry Anden finansiel formidling undtagen forsikring og pensionsforsikring, i.a.n.. The company was previously named Komplementarselskabet Resireal NSF-Innovater A3 ApS. In 2022, the company reported a net result of DKK -7,000 compared with DKK -7,000 the year before. Equity in the 2022 report amounted to DKK 12,000.